Hypoxia and the hypoxia inducible factor 1α activate protein kinase A by repressing RII beta subunit transcription

Kristin Lucia1,2,7,8 · Yonghe Wu3 · Jose Monteserin Garcia1 · Anne Barlier4 · Michael Buchfelder5 · Wolfgang Saeger6 · Ulrich Renner1 · Günter K. Stalla1,2 · Marily Theodoropoulou1,2

Received: 2 September 2019 / Revised: 9 February 2020 / Accepted: 12 February 2020 / Published online: 28 February 2020
© The Author(s) 2020. This article is published with open access

Abstract
Overactivation of the cAMP signal transduction pathway plays a central role in the pathogenesis of endocrine tumors. Genetic aberrations leading to increased intracellular cAMP or directly affecting PKA subunit expression have been identified in inherited and sporadic endocrine tumors, but are rare indicating the presence of nongenomic pathological PKA activation. In the present study, we examined the impact of hypoxia on PKA activation using human growth hormone (GH)-secreting pituitary tumors as a model of an endocrine disease displaying PKA-CREB overactivation. We show that hypoxia activates PKA and enhances CREB transcriptional activity and subsequently GH oversecretion. This is due to a previously uncharacterized ability of HIF-1α to suppress the transcription of the PKA regulatory subunit 2B (PRKAR2B) by sequestering Sp1 from the PRKAR2B promoter. The present study reveals a novel mechanism through which the transcription factor HIF-1α transduces environmental signals directly onto PKA activity, without affecting intracellular cAMP concentrations. By identifying a point of interaction between the cellular microenvironment and intracellular enzyme activation, neoplastic, and nonneoplastic diseases involving overactivated PKA pathway may be more efficiently targeted.

Introduction

The protein kinase A (PKA)-signaling cascade transduces physiological hormone mediated processes and its deregulation plays a central role in the pathogenesis of neoplastic as well as nonneoplastic diseases. The PKA tetrameric holoenzyme is composed of regulatory (R) and catalytic (C) subunit dimers. The regulatory subunits are each present in alpha (α) and beta (β) isoforms (RIα, RIIα, RIβ, and RIIβ) and their expression and tissue-specific balance are essential in shaping the specificity and degree of its activity [1, 2]. When in the R2C2 conformation, PKA is catalytically inactive. Following the binding of the second messenger 3′,5′-cyclic adenosine monophosphate (cAMP) to the regulatory subunit dimer, a conformational change occurs which allows the active catalytic subunit to dissociate and phosphorylate serine/threonine residues of substrate proteins, like cAMP-responsive element (CRE) binding protein (CREB) [3–5]. PKA is deregulated in several human cancers and in particular in endocrine tumors such as thyroid cancer, adrenal tumors (Cushing’s syndrome, Carney complex), and GH-secreting pituitary tumors (acromegaly) as a result of altered expression of its subunits [6–8].

Acromegaly is an endocrine neoplastic condition caused by excessive GH secretion from tumors of the anterior
pituitary gland [9]. Under physiological conditions hypophysial stimuli trigger GH synthesis by activating the cAMP/PKA-signaling cascade and somatostatin analogs that inhibit this pathway are the mainstay pharmacological treatment for patients with acromegaly [10]. Therefore, the pathophysiology of these tumors is tightly linked to an overactivated PKA-signaling cascade that in 40% of cases is due to activating mutations of the guanine nucleotide binding protein (G protein), alpha stimulating activity polypeptide 1 (GNAS1) gene (gsp oncogene) encoding for the Gαs subunit [11]. Recent whole-genome and -exome sequencing studies in acromegalic patients did not reveal any novel recurrent somatic mutations, which could account for the PKA overactivation in more than half of GH-secreting pituitary tumor cases [12, 13]. In contrast, an intriguing pathological feature of these tumors is their decreased vascular density when compared with the non-tumorous anterior pituitary tissue [14].

Decreased vascular density is frequently observed in solid tumors where it leads to relative tissue hypoxia [15]. The cellular response to tissue hypoxia involves the oxygen-dependent stabilization and activation of a family of transcription factors known as hypoxia inducible factors (HIFs). HIF-1α is a well characterized member of the HIF family and is upregulated in various cancers compared with nontumorous tissues [16, 17]. Under nonhypoxic conditions, the activity of oxygen-dependent prolyl hydroxylases marks HIF-1α for VHL mediated ubiquitination and subsequent proteosmal degradation [18]. When the cellular oxygen concentration drops to near 2% O2, prolyl-hydroxylase activity is inhibited and HIF-1α remains stabilized and translocates to the nucleus where it associates with cofactors and binds to its cognate DNA motif thereby initiating the transcription of target genes [19, 20]. HIF-1α directly regulates adaptive processes, which can confer a survival advantage to cells in a hypoxic tissue microenvironment such as metabolic reprogramming towards a glycolytic phenotype, pH regulation, and nutrient uptake [21–24].

While germline and somatic mutations in the genes encoding for PKA regulatory subunits have been characterized, they are infrequent and little is known about nongenomic effectors of aberrant PKA activity in human tumors [7, 8, 25]. The role of the tumor microenvironment in shaping the phenotype of AIP-mutation-positive somatotroph tumors recently been highlighted [26]. We therefore hypothesized that the decreased vascular density observed in acromegalic pituitary tumors may contribute to the activated PKA found in the absence of stimulating gsp mutations. Studies in tissues under hypoxia due to myocardial or cerebral infarction demonstrated high phosphorylation levels of the PKA substrate CREB, suggesting that low oxygen availability may indeed influence PKA activity [27, 28]. In addition, there is evidence that hypoxia affects the intracellular location of PKA and subsequently its function [25]. Accordingly, the aim of this study was to investigate the nongenomic effect of hypoxia on PKA activation using GH-secreting pituitary tumor cells as a model.

We observed that human acromegalic tumors, but not the normal pituitary gland, present with HIF-1α immunoreactivity (IR) indicative of hypoxic state. In primary human tumor cell cultures as well as immortalized pituitary tumor cells, hypoxia, and HIF-1α increased PKA activity and its downstream targets CREB and GH synthesis without affecting intracellular cAMP concentrations. We show that HIF-1α represses the transcription of the gene encoding for RIIβ (PRKAR2B) by interacting with Sp1 and sequestering it from the promoter. The selective overexpression of RIIβ abolished the effects of HIF-1α on PKA activation and its downstream targets, suggesting that the decreased PRKAR2B transcription under hypoxia is sufficient to increase PKA activity. Indeed, human acromegalic tumors showed reduced PRKAR2B transcript levels that were negatively correlated with HIF-1α protein. Altogether these data showcase the important role of HIF-1α on PKA regulation which not only has consequences in the pathogenesis of endocrine tumors and their response to treatment, but may also provide a basis for intervening in nonneoplastic diseases such cardiac disorders in which hypoxia and PKA activation also play a central role.

Materials and methods

Compounds and antibodies

The adenylyte cyclase activator forskolin was obtained from Sigma (St. Louis, MO, USA). Primary antibodies used in this study were: CREB (Cell Signaling, Cat. 86B10—western Blot, ChIP), phospho-CREB Ser133 (Cell Signaling Cat. 87G3—western Blot) Anti-FLAG M2 (Sigma, Cat. F3165—western Blot), Anti-HIF-1α (Novus, Cat. NB100134—western Blot, Immunohistochemistry, Co-Immunoprecipitation, ChIP), Pit-1 (Santa Cruz Cat. Sc-442—western Blot, ChIP), PP1a (Santa Cruz Cat. Sc-7482—western Blot), Anti-HIF-1α (Novus, Cat. NB100134—western Blot, Immunohistochemistry, Co-Immunoprecipitation, ChIP), Pit-1 (Santa Cruz Cat. Sc-442—western Blot, ChIP), PP1a (Santa Cruz Cat. Sc-7482—western Blot), Sp1 (Santa Cruz Cat Sc59X—western Blot, ChIP), and PKA IIB Reg—H90 (Santa Cruz Cat. sc-25424). Secondary Antibodies conjugated to HRP (rabbit and mouse) used for western blot were obtained from Cell Signaling. Biotinylated Rabbit IgG for immunohistochemistry was obtained from Vector (Cat. BA1000). Normal rabbit and mouse IgG were obtained from Santa Cruz and used as negative controls for co-immunoprecipitation and ChIP studies.
**Immunohistochemistry**

The tissue processing and immunohistochemistry of 39 paraffin embedded human GH-secreting pituitary tumors was performed as previously described [29]. All samples were obtained from patients undergoing transsphenoidal tumor resection following signed and informed consent and after approval of the local ethics committee. Following staining, the IR of HIF-1α was scored according to the following scheme: 1 = 10–30% IR, 2 = 31–60% IR, and 3 = 61–100% IR. Nine nondiseased human pituitary glands were obtained from autopsy cases of sudden death with no evidence of endocrine diseases, taken 8–12 h postmortem. Normal pituitary samples were subjected to the same processing and scoring as described for tumor samples. The removal and use of pituitary tissue was approved by the ethics committee of the Max-Planck-Institute of Psychiatry and informed consent was received from the relatives of donors.

**Cell culture**

The rat GH-secreting pituitary tumor cell line GH3 was obtained from ATCC and cultured for maintenance in DMEM (Gibco 41965) supplemented with 10% heat inactivated fetal calf serum (Gibco 10270), 100 U ml⁻¹ penicillin/streptomycin (Biochrom) and 2 nM glutamine (Biochrom). Processing and culturing of primary human acromegalic tumors was performed as previously described [30].

**Hypoxia chamber**

The hypoxic treatment of cells was performed in a modular hypoxia incubator chamber (StemCell Technologies, Cat. 27310). For hypoxic incubation, cells were placed in the center of the chamber which was sealed shut and connected via a flow meter (StemCell Technologies, Cat. 27311) to a gas tank containing 1% O₂, 5% CO₂, and 94% N₂. The modular chamber was placed in a standard humidified incubator at 37° for 6–12 h. A normoxic control was placed in the same incubator outside of the hypoxia chamber. Control of hypoxia was performed either by western blot for HIF-1α protein expression or hypoxia responsive element (HRE)-luciferase assay.

**Western blot**

Sample preparation of snap-frozen tissue (human normal anterior pituitary gland and acromegalic pituitary tumors) was performed as follows: tissue samples were homogenized in ice-cold RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) using an Ultra-Turrax. GH3 cell lysates were in RIPA buffer and disrupted using a 20G insulin needle. Protein concentration was determined with the Bradford manufacturer’s instructions, at OD₆₃₀nm.

**Co-immunoprecipitation**

Co-immunoprecipitation experiments in GH3 cells were performed on the nuclear fractions. For fractionation cells were collected by careful scraping and pelleted by centrifugation. The cell pellet was carefully resuspended in hypotonic cell lysis buffer and incubated on ice for 15 min. Following centrifugation, the supernatant was decanted and cells were disrupted again in hypotonic lysis buffer using a 20G insulin syringe and centrifuged. The supernatant containing the cytoplasmic fraction was separated and 75 µl of cell extraction buffer was used to resuspend the pellet. A final centrifugation step was performed and the supernatant containing the nuclear fraction was separated to a clean tube and subjected to preclearing for 30 min at 4 °C using 10 µL Protein G Dynabeads per 10⁶ cells. The immunoprecipitation reaction was performed using Protein G Dynabeads coupled to the primary antibody in a separate reaction. In total, 10 µL of the antibody-bead complexes were given to 30 µL of precleared lysates. Following rotation overnight at 4 °C, immune complexes were washed and suspended in sample buffer (Roti-Load 1, Roth) to be immunoblotted as described above.

**Chromatin immunoprecipitation**

GH3 cells were processed with the EZ ChIP chromatin immunoprecipitation kit (Upstate), using rabbit anti-Pit-1 (Santa Cruz), anti-CREB (Cell Signaling), anti-HIF-1α (Novus), and anti-Sp1 (Santa Cruz) antibodies. Normal rabbit and mouse IgGs were used as negative control for the respective immunoprecipitation reactions. Primers against the rat Gh promoter were previously described [31]. Primers against the rat Pit-1 promoter were 5′-TGACGTCAAAT AAAGTTTCTGTAAAAAA-3′ and 5′-TGTTAACCCGAACTG TCTTTCTTAC-3′ (Eurofins MWG Operon), and primers against rat Prkar2B were 5′-CACCAATGTGGAGGCTG AAGT-3′ and 5′-GCAAATCCACGTTTCTTTCT-3′.

**PP1 activity**

Phosphatase activity was measured using the Ser/Thr phosphatase assay kit 1 (Upstate) according to the manufacture’s instructions, at OD₆₃₀nm.
PKA activity assay

The PepTag Nonradioactive Protein Kinase Assay Kit (Promega, Madison, USA) was used according to the manufacturer’s instructions. Imaging of the phosphorylated peptide substrate was performed using a Chemiluminescent reagent (Bio-Rad) and densitometric quantification was performed using Bio-Rad ImageLab 4.1 software.

Plasmid transfection, RNA interference, and reporter assays

GH3 cells were transfected using SuperFect (Qiagen) [32]. Single-interfering RNAs (siRNAs) were against rat HIF-1α (Santa Cruz Cat. sc-45919) and rat Creb1 (Santa Cruz Cat. sc-72030) and nonspecific scramble control (Santa Cruz Cat. sc-37007). The following expression plasmids were used: M7 pdn-PKA-GFP (Randall Moon; Addgene plasmid # 16716), RSV CREB (Marc Montminy; Addgene plasmid # 22394), RSV CREB-M1 (Marc Montminy; Addgene plasmid # 22395), PRKAR2B (Origene, SKU SC125501), and pCMV-3xFLAG-HIF-1α (gift of Eduardo Arzt (Buenos Aires Argentina)). In vitro mutagenesis was performed to change the Arginine30 to Alanine in the pCMV-3xFLAG-HIF-1α plasmid (QuickChange II-Direct Mutagenesis Kit, Agilent Technologies), and constructs were verified by sequencing (Sequiserve, Vaterstetten Germany). Luciferase reporter constructs used in this study were as follows: HRE-luciferase, a gift from Navdeep Chandel (Addgene plasmid # 26731) contains three hypoxia response elements from the Pgk-1 gene upstream of firefly luciferase. The pA3GHluc GH-luciferase, a gift from A. Gutierrez-Hartmann, Denver USA, has the proximal (-593) rat GH promoter upstream to the luciferase gene. The pCRE-luc construct (Mercury pathway profiling system; Clontech Laboratories, Mountain View, CA, USA) has the CRE upstream to the TATA box of the herpes simplex virus thymidine kinase promoter and firefly luciferase. The reporter genes were cotransfected with RSV-βGal. Luciferase activity was measured using a TriStar and galactosidase activity (p-Nitrophenyl β-D-galactopyranoside) in an absorbance plate reader at 405 nm. Relative luciferase values (Luc/Gal) were applied to normalize for transfection efficiency.

Radioimmunoassays

Rat GH was measured as previously described [33]. Human GH was measured using a commercial kit (DRG Diagnostics, Cat. RIA-0225). To correct for possible effects of hypoxic incubation and transfection on the proliferation of GH3 cells, cell proliferation was measured in parallel using the nonradioactive WST-1 assay (Roche) and used to normalized GH values. Rat intracellular cAMP was measured using a commercial kit (Perkin Elmer, Cat. NEK033).

Quantitative real-time RT-PCR (qPCR)

Total RNA was extracted from cells and tissues with Trizol reagent (Life Technology) according to the manufacturer’s instructions. Total of 1 μg RNA was reverse transcribed using the QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturer’s instructions. Quantitative real-time PCR was performed on a capillary LightCycler (Roche) using the QuantiFast SYBR Green PCR Kit (Qiagen) at a final volume of 10 μl. Expression levels of the housekeeping genes (human β-actin and rat THI-β) were used for normalization. In the case of human pituitary tumors, only those that had been screened by conventional PCR for the presence of normal pituitary tissue in the sample were included in the study as previously described [34].

Gsp mutation analysis

DNA from human acromegalic pituitary tumors (snap frozen) was used for the analysis of the gsp mutation status as previously described [11].

Statistical analysis

Statistical analysis was performed using SPSS (PASW Statistics) 18. Differences in human tissue samples were assessed using the nonparametric Mann–Whitney U-Test with P < 0.05 considered as significant in samples with similar variance. Differences in cell line experiments were assessed using the Student’s t test with P < 0.05 considered as significant. Analysis of patient data was performed using linear regression analysis and Pearson’s rho with P < 0.05. Experiments with full data/replicate values were included for statistical analysis.

Results

HIF-1α is overexpressed in GH-secreting pituitary tumors

Immunohistochemistry performed on archival paraffin embedded GH-secreting pituitary tumors from patients with acromegaly and normal autopsy pituitary samples showed abundant nuclear HIF-1α staining in acromegalic tumors and virtually absent staining in the normal pituitary (Fig. 1a). These results were confirmed in western blot analysis which demonstrated strong expression in acromegalic tumors but absent HIF-1α signal in the normal pituitary (Fig. 1b, c). HIF-1α stability is mainly posttranscriptionally regulated, and while HIF-1α transcripts were detected in both normal pituitaries and acromegalic tumors, no significant differences were measured (Fig. 1d) indicating that
the increased HIF-1α transcription per se is not responsible for the abundant protein expression observed in acromegalic tumors. As GH-secreting tumors carry oncogenic gsp mutations in 40% of cases [35], we examined the possible association between gsp status and HIF-1α protein levels in 21 acromegalic tumors (Table 1). Linear regression analysis showed no significant predictive value of the presence of the gsp oncogene on HIF-1α protein expression (Table 1). These data suggest that the increased HIF-1α expression does not occur secondary to gsp oncogenic mutations.

**HIF-1α mediates the effects of hypoxia on GH synthesis**

To examine the impact of HIF-1α on PKA activity we first studied its effect on GH synthesis, which is tightly regulated by the PKA-signaling cascade [36–39] and is therefore a physiologically relevant readout of PKA activity. Primary cultures of human GH-secreting tumors incubated under hypoxia (1% O_2 for 18 h) showed a significant increase in GH secretion compared with parallel normoxic cultures of the same tumor (Fig. 2a). Similarly, immortalized GH-secreting pituitary tumor GH3 cells incubated under hypoxic conditions showed increased rat Gh promoter activity, transcription and hormone secretion, and these effects were abrogated by knocking down HIF-1α with RNA-interference (Fig. 2b–d). Transient overexpression of HIF-1α also significantly increased Gh promoter activity as well as transcription and secretion (Fig. 2e–g). An HIF-1α construct unable to bind to the consensus HRE due to a single amino acid mutation in its DNA-binding domain (HIFαR30A) [40] also increased Gh promoter activity to a similar extent as the wild-type HIF-1α (Fig. 2h, Supplementary Figs. 1 and 2), indicating that HIF-1α was not directly promoting growth hormone transcription via promoter binding. In addition, chromatin immunoprecipitation showed no enrichment of HIF-1α on the Gh promoter in contrast to the abundant binding of Pit-1 which was used as positive control [41] (Fig. 2i). These results effectively rule out a direct DNA binding as the cause of HIF-1α–induced GH synthesis and point to an integration point upstream to its transcription.

**HIF-1α affects CREB phosphorylation and transcriptional activity**

Pituitary GH transcription is stimulated by CREB both directly, through the binding to its canonical CRE promoter sequences, and indirectly by promoting the transcription of the POU1F1 gene, which encodes for Pit-1 [36, 41, 42]. Indeed, CREB inhibition with RNA interference abrogated the ability of hypoxia to increase rat Gh transcription (Fig. 3a). Hypoxia significantly increased CRE transcriptional activity in a HIF-1α-dependent manner (Fig. 3b), and HIF-
CREBS133A mutant (CREB-M1) that cannot be phosphorylated (Supplementary Fig. 5). In contrast, overexpression of a protein expressing was observed (F(1,20) = 0.025), indicating the importance of CREB phosphorylation in hypoxia’s action.

**HIF-1α and hypoxia activate PKA**

PKA is the major kinase phosphorylating CREB [48, 49]. Both HIF-1α overexpression and hypoxic incubation significantly increased PKA activity (Fig. 4a, b). Over-expression of a dominant negative catalytically inactive PKA in GH3 cells abolished the stimulatory action of hypoxia on GH promoter activity, transcription, and secretion (Fig. 4c–e), demonstrating that hypoxia and consequently HIF-1α requires a catalytically active PKA to mediate its effects. PKA activation first occurs following an increase in intracellular cAMP concentrations [48, 49]. However, neither HIF-1α inhibition with RNA interference nor hypoxic incubation affected basal and forskolin-induced intracellular cAMP levels (Fig. 4f, g), indicating that HIF-1α activates PKA independently of cAMP.

**HIF-1α suppresses Prkar2b transcription**

PKA activity can be dysregulated as a result of altered subunit expression patterns activity [48, 49]. As a transcriptional regulator, we therefore speculated that HIF-1α may induce basal PKA activity by altering the balance of the expression of the different PKA subunits. HIF-1α overexpression and incubation under hypoxic conditions significantly suppressed the expression of the gene encoding for RIIβ (Prkar2b) and did not significantly affect the expression of the genes encoding for the other regulatory subunits (Prkar1a, Prkar1b, and Prkar2a) and the catalytic subunit (Prkaca) (Fig. 5a). Similarly, overexpression of both wild type and the HIF-1αR30A suppressed Prkar2b transcription, whereas HIF-1α inhibition using RNA interference increased Prkar2b gene transcription (Fig. 5b). To determine whether the decreased expression of the Prkar2b gene impacts the catalytic activity of the PKA enzyme we reduced its expression with three different siRNA constructs and observed increase in PKA activity (Fig. 5c). In contrast, overexpression of the regulatory RIIβ subunit compromised the stimulatory action of hypoxia on PKA activity and blunted its effects on GH synthesis (Fig. 5d–g).

These observations suggest that hypoxia via HIF-1α may render PKA active by suppressing Prkar2b transcription. Prkar2b gene transcription is regulated by the transcription factor Sp1 that binds on the GC-rich sequences of its promoter [50, 51]. As HIF-1α is able to bind and sequester Sp1 [52], we investigated whether it may physically interact with and sequester it away from the endogenous Prkar2b promoter in GH3 cells. Indeed, chromatin immunoprecipitation experiments revealed that GH3 cells overexpressing HIF-1α showed decreased Sp1 enrichment to the Prkar2b

---

**Table 1** Patient cohort used for mRNA and protein screening.

| Case Nr. | Sex | Age | Grade | Gsp status | Gsa mRNA | HIF-1α protein |
|----------|-----|-----|-------|------------|-----------|----------------|
| 1        | M   | 61  | II    | –          | 557       | 113            |
| 2        | M   | 31  | II    | –          | 57        | 196            |
| 3        | M   | 50  | III   | +          | 475       | 200            |
| 4        | M   | 38  | II    | +          | 729       | 188            |
| 5        | F   | 54  | III   | –          | 755       | 161            |
| 6        | F   | 37  | III   | –          | 999       | 348            |
| 7        | F   | 30  | III   | –          | 175       | 216            |
| 8        | F   | 51  | III   | –          | 170       | 180            |
| 9        | M   | 51  | III   | –          | 684       | 231            |
| 10       | M   | 49  | III   | –          | 668       | 5              |
| 11       | M   | 24  | II    | –          | 288       | 429            |
| 12       | M   | 43  | III   | –          | 858       | 56             |
| 13       | M   | 46  | III   | –          | 734       | 80             |
| 14       | M   | 34  | II    | +          | 330       | 190            |
| 15       | M   | 83  | III   | –          | 168       | 332            |
| 16       | M   | 72  | II    | –          | 324       | 162            |
| 17       | F   | 38  | III   | +          | 207       | 147            |
| 18       | M   | 36  | II    | +          | 332       | 168            |
| 19       | M   | 57  | I     | –          | 997       | 322            |
| 20       | M   | 42  | III   | –          | 174       | 165            |
| 21       | M   | 32  | III   | +          | 239       | 123            |

Patient cohort of the 21 acromegalic tumors that were analyzed by real-time PCR, western blot, and gsp mutational status. No significant predictive value of the presence of the gsp mutation status on HIF-1α protein expression was observed (F(1,20) = 0.479, P = 0.497, R² = −0.025).
promoter compared with IgG controls (Fig. 6a, d). No promoter enrichment of HIF-1α on Prkar2b was observed confirming that it does not affect Prkar2b transcription by direct DNA binding. Hypoxia, HIF-1α silencing, and
transient overexpression of HIF-1α did not affect Sp1 transcription (Supplementary Fig. 7). However, HIF-1α co-immunoprecipitated with Sp1 in hypoxic GH3 cells confirming their physical interaction in pituitary tumor cells (Fig. 6b, e).

This observation suggests that high levels of HIF-1α may compromise PRKAR2B transcription. Indeed in GH-secreting pituitary tumors from patients with acromegaly (n = 10), we confirmed a significant decrease in PRKAR2B expression (Fig. 6a) and a significant increase in HIF-1α expression compared with normal anterior pituitary glands (Fig. 6c, a) and this was also shown at protein level (Fig. 6d, b). In contrast, no significant changes were observed in the expression of the genes encoding for all the other subunits (Supplementary Fig. 8). In addition, we observed a significant negative correlation between HIF-1α protein and Pit-1 (encoding for Pit-1) promoter in GH3 cells overexpressing HIF-1α. Rabbit IgG was used as a control. Data are arbitrary units from two independent experiments, presented as% of input. **P<0.01 (Student’s t test).

Fig. 3 Hypoxia and HIF-1 trigger CREB activity. a Knocking down CREB with siRNA abolishes the effect of hypoxia on endogenous rat Gh transcription in GH3 cells as determined by real-time RT-PCR. Immunoblot shows the knockdown efficacy of the CREB siRNA (b) effect of hypoxia (1% O2 for 18 h) on CRE induced luciferase activity. Transfection with 100 nM HIF-1α siRNA for 48 h abolished the effect of hypoxia. Luc/βGal: luciferase: β-galactosidase ratio. Data are means±SEM of three experiments and expressed as percentage of each normoxia control. *P<0.05 (Student’s t test). c Effect of HIF-1α overexpression on CRE luciferase activity. Data are means±SEM of three experiments and expressed as percentage of mock control. *P<0.05 (Student’s t test). d Chromatin immunoprecipitation showing increased CREB binding to the endogenous rat Pou1f1 (encoding for Pit-1) promoter in GH3 cells overexpressing HIF-1α. Rabbit IgG was used as a control. Data are arbitrary units from two independent experiments, presented as% of input. **P<0.01 (Student’s t test).

This observation suggests that high levels of HIF-1α may compromise PRKAR2B transcription. Indeed in GH-secreting pituitary tumors from patients with acromegaly
**Discussion**

In cancer, hypoxia has long been recognized as a contributing factor to the development and survival of tumor cells [53], and HIF-1α has been identified as a key mediator of the adaptive processes which confer a survival advantage in the hypoxic tumor microenvironment [21, 22, 54]. Our findings delineate a novel pathogenic mechanism through which HIF-1α can amplify PKA signaling independently of gsp mutations or intracellular cAMP concentrations. In GH-secreting tumors, whose pathophysiology is closely linked to PKA activity, we show that HIF-1α suppresses the transcription of the gene that encodes for RIIβ thereby promoting PKA activation, which in turn leads to greater activation of downstream targets such as CREB and ultimately promotes excessive GH synthesis.

There has been previous evidence that hypoxia and HIF-1α may affect PKA activity. First, in a model of melanoma it was demonstrated that the PKA scaffold protein AKAP12v2 is a direct transcriptional target of HIF-1α, and its hypoxic induction effectively enhances the migratory capacity of melanoma cells [25]. At the organelle level, hypoxia can promote the ubiquitination and degradation of the mitochondrial AKAP121, therefore attenuating PKA-CREB signal transduction to the outer mitochondrial membrane during brain ischemia [55]. Finally, in A549 lung cancer cells it was shown that long-term (2 days) hypoxic incubation can increase the relative expression of...
**Fig. 5** Hypoxia and HIF-1α downregulates the transcription of gene encoding for the PKA regulatory subunit RIIβ. a Expression of the genes encoding for PKA regulatory and catalytic subunits in GH3 cells grown under hypoxic conditions (1% O2 for 18 h) as determined by real-time RT-PCR. Data are <gene name>/TFIIb, means ± SEM from two experiments and presented as fold change to each normoxia. **P<0.01 to each normoxia (NX) (Student’s t test). b Effect of HIF-1α overexpression or knockdown with siRNA on Prkar2b transcription. *P<0.05 to pCMV empty vector, **P<0.01 to scrambled siRNA control (Student’s t test). c Two siRNA constructs targeting Prkar2b in GH3 cells caused an increase in PKA activity. Data are means representative of the two individual constructs and expressed as % of control siRNA. Hypoxia (1% O2 for 18 h) has no effect on (** Fold Increase vs. NX) PKA activity. e. g. the sole trigger of overactive PKA under these conditions. Therefore, PRKAR2B poses to be the first direct target of HIF-1α within the PKA holoenzyme.

Previous studies have shown that loss of RIIa/β is associated with more aggressive tumor behavior [49, 58, 59], while the expression of RIIα/β promotes cell cycle arrest [52, 60]. In this sense, our findings that suppression of RIIβ in pituitary tumor cells leads to increased PKA activity and GH hypersecretion are in line with these previous findings. However, as RIIα/β and RIIα/β are not only functionally nonredundant but also display a tissue-specific pattern of distribution [57], we believe the effects of loss or gain of a specific isoform should not be generalized without biological validation in the particular system of interest.

To date, the regulatory Iα subunit has been of particular interest in the pituitary as mutations mapping to its locus at 17q22-24 are commonly found in patients with Carney Complex, a multiple neoplasia syndrome which is associated with abnormal GH and prolactin secretion [7]. Large-scale genetic screening of sporadic acromegalic cases have
revealed no loss of PRKAR1A gene expression indicating that PRKAR1A mutations are not involved in GH hypersecretion outside of the Carney Complex [12, 13, 50]. Given the paucity of evidence supporting mutations of the PKA subunits as being causative of GH hypersecretion in sporadic cases, our study presents a novel nongenomic mechanism through which HIF-1α acts as a surrogate of the tumor microenvironment to influence GH synthesis.

We found that HIF-1α downregulates PRKAR2B transcription but we did not detect any direct binding to its promoter. While HIF-1α can directly activate the transcription of a multitude of target genes via its constitutive DNA binding domain (CGTC), its role in transcriptional repression remains less well characterized. Genome-wide association studies of HIF-1α DNA binding and transcription profiling have shown that HIF-1α-dependent gene suppression most commonly occurs through indirect mechanisms such as the HIF-1α upregulates the transcription of transcriptional repressors that then suppress the expression of the affected genes [51, 61].

**Fig. 6** HIF-1α modulates PRKAR2B expression via Sp1 promoter binding and their expression levels are inverse correlated in acromegalic tumors. a, d Chromatin immunoprecipitation showing decreased Sp1 binding on the Prkar2b promoter in GH3 cells overexpressing HIF-1α. No DNA binding was quantified with HIF-1α. Rabbit IgG was used as control. b, e Co-immunoprecipitation experiment showing that both HIF-1α and HIF-1α R30A physically associate with Sp1. HIF-1α and Sp1 immunoprecipitates were blotted for Sp1. Proteins immunoprecipitated with rabbit IgG were used as controls. c, a Expression of PRKAR2B gene in normal pituitary glands (n = 9) and acromegalic tumors (ACRO, n = 10). Data are PRKAR2B/TFIIB arbitrary units. *P = 0.006 (U-test). d, b Western blot analysis of normal pituitary (NP) and GH-secreting tumors (ACRO) showed a significant loss of PRKAR2B protein expression, whereas HIF-1α protein levels measured in the same tumors are significantly increased in ACRO vs NP (n = 4 per group due to scarcity of material for dual measurement). e, c Linear regression analysis of PRKAR2B transcript and HIF-1α protein levels in 14 acromegalic tumors. PRKAR2B was determined by real-time RT-PCR and values are PRKAR2B/TFIIB arbitrary units. HIF-1α protein was quantified from immunoblots (Chemidoc). Kendall’s τ = −0.663, r = −0.480, P = 0.009.
characterized mechanism is through physical interaction and sequestration of transcription factors from their target promoter sequence. In this context, HIF-1α was shown to compete with Sp1 for c-Myc, resulting in the transcriptional repression of the Myc target gene MutSα [62]. The PRKAR2B promoter has CG-rich regions with Sp1-binding sites [63, 64]. We found that HIF-1α physically interacts with and decreases Sp1 binding from the Prkar2b promoter therefore supporting the concept of HIF-1α-mediated transcriptional repression beyond the HRE-dependent regulation of gene expression. This effect of HIF-1α occurs solely by sequestering Sp1 and does not affect total Sp1 levels. These results point to a general mechanism through which HIF-1α may suppress the transcription of genes with CG-rich promoters.

A considerable amount of work has described the regulation action of PKA on HIF-1α [65]. Upstream PKA activators modulate HIF-1α transcriptional activation of target genes such as VEGF-A in lung cancer models [66]. In fact, PKA directly phosphorylates HIF-1α in endothelial cells under intermittent hypoxia [67]. Indeed, two putative PKA phosphorylation sites on HIF-1α Thr63 and Ser692 physically interact with and decreases Sp1 binding from the Prkar2b promoter therefore supporting the concept of HIF-1α-mediated transcriptional repression beyond the HRE-dependent regulation of gene expression. This effect of HIF-1α occurs solely by sequestering Sp1 and does not affect total Sp1 levels. These results point to a general mechanism through which HIF-1α may suppress the transcription of genes with CG-rich promoters.

Taken together with our findings of a novel mechanism of PKA activation through HIF-1α, the possibility of a feed-forward loop between HIF-1α and PKA may be of significant interest in regards to examining nongenomic mechanisms of PKA activation in both neoplastic and nonneoplastic diseases. Our studies in GH-secreting pituitary tumor cells provide with a new link between an environmental stressor in the form of hypoxia and an important intracellular physiological regulator of pituitary function. Given the diversity of cellular processes which are coordinated by PKA [70, 71], these observations may have implications reaching beyond endocrine pathology.

Acknowledgements Open access funding provided by Projekt DEAL.

Compliance with ethical standards

Conflict of interest The authors declare no competing financial interests in relation to the work described. The paper material is original research, has not been previously published and has not been submitted for publication elsewhere while under consideration.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Amieux PS, Cummings DE, Motamed K, Brandon EP, Wailes LA, Le K, et al. Compensatory regulation of Ralpha protein levels in protein kinase A mutant mice. J Biol Chem. 1997;272:3993–8.
2. Brandon EP, Logue SF, Adams MR, Qi M, Sullivan SP, Matsuno AM, et al. Defective motor behavior and neural gene expression in Rbeta-protein kinase A mutant mice. J Neurosci. 1998;18:3639–49.
3. Mellon PL, Clegg CH, Correll LA, McKnight GS. Regulation of transcription by cyclic AMP-dependent protein kinase. Proc Natl Acad Sci USA. 1989;86:4887–91.
4. Adams JA, Taylor SS. Energetic limits of phosphotransfer in the catalytic subunit of cAMP-dependent protein kinase as measured by viscosity experiments. Biochemistry. 1992;31:8516–22.
5. Kim C, Cheng CY, Saldanha SA, Taylor SS. PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell. 2007;130:1032–43.
6. Sandrini F, Matyakhina L, Sarlis NJ, Kirschner LS, Farmakidis C, Gimm O, et al. Regulatory subunit type I-alpha of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer. Genes Chromosomes Cancer. 2002;35:182–91.
7. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzikas C, Cho YS, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet. 2000;26:89–92.
8. Beuschlein F, Fassnacht M, Assié G, Calebiro D, Stratakis CA, Osswald A, et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N Engl J Med. 2014;370:1019–28.
9. Melmed S. Acromegaly pathogenesis and treatment. J Clin Investog. 2009;119:3189–202.
10. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–51.
11. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, et al. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab. 1998;83:1604–10.
12. Välimäki N, Demir H, Pitkänen E, Kaasinen E, Karpinnen A, Kivipelto L, et al. Whole-genome sequencing of growth hormone (GH)-secreting pituitary adenomas. J Clin Endocrinol Metab. 2015;100:3918–27.
13. Ronchi CL, Peverelli E, Herterich S, Weigand I, Mantovani G, Schwarzmayr T, et al. Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Eur J Endocrinol. 2016;174:363–72.
14. Turner HE, Naga Z, Gatter KC, Esiri MM, Harris AL, Wass JA. Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab. 2000;85:1159–62.

15. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393–410.

16. Zhong H, De Marzo AM, Laugher E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830–5.

17. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157:411–21.

18. Epstein AC, Gleedle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43–54.

19. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–32.

20. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 {alpha} is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92:5510–4.

21. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123:3664–71.

22. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47.

23. Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, et al. Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology. 1989;125:699–706.

24. Ezzat S, Yu S, Asa SL. The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. Mol Endocrinol. 2005;19:1004–11.

25. Finger EC, Castellini L, Rankin EB, Vilalta M, Jiang D, et al. Hypoxia-inducible factor 1alpha is a basic-helix-loop-helix-PAS heterodimer regulated by prolyl hydroxylation. Cell. 2000;107:43–54.

26. Barry S, Carlsen E, Marques P, Stiles CE, Gadaleta E, Berney DM, et al. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene. 2019;38:5381–95.

27. Prabu SK, Anandatheethavarakar HD, Raza H, Srinivasan S, Spear JE, Avadhani NG. Protein kinase A-mediated phosphorylation modulates cytochrome c oxidase function and augments hypoxia and myocardial ischemia-related injury. J Biol Chem. 2006;281:2061–70.

28. Kitagawa K. CREB and cAMP response element-mediated gene expression in the ischemic brain. FEBs J. 2007;274:3210–7.

29. Theodoropoulou M, Cavallari I, Barzon L, D’Agostino DM, Ferro T, Arzberger T, et al. Differential expression of menin in sporadic pituitary adenomas. Endocr Relat Cancer. 2004;11:333–44.

30. Stalla GK, Stalla J, von Werder K, Müller OA, Gerzer R, Höllt V, et al. Nitromidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology. 1989;125:699–706.

31. Ezzat S, Yu S, Asa SL. The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. Mol Endocrinol. 2005;19:1004–11.

32. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006;66:1576–82.

33. Arzt E, Buric R, Stelzer G, Stall a J, Sauer J, Renner U, et al. Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6. Endocrinology. 1993;132:459–67.

34. Pagotto U, Arzberger T, Theodoropoulou M, Grüber Y, Pantaloni C, Saeger W, et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 2000;60:6794–9.

35. McCormick A, Brady H, Theill LE, Karin M. Regulation of the pituitary-specific homeobox gene GHF1 by cell-autonomous and environmental cues. Nature. 1990;345:829–32.

36. Basso F, Rocchetti F, Rodriguez S, Nesterova M, Cormier F, Stratakis CA, et al. Comparison of the effects of PRKAR1A and PRKAR2B depletion on signaling pathways, cell growth, and cell cycle control of adrenocortical cells. Horm Metab Res. 2014;46:883–8.
50. Sandrini F, Kirschner LS, Bei T, Farmakisidis C, Yasufuku-Takano J, Takano K, et al. PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. J Med Genet. 2002;39:e78.

51. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 2009;284:16767–75.

52. Elliott MR, Tolnay M, Tsokos GC, Kammer GM. Protein kinase A regulatory subunit type II beta directly interacts with and suppresses CREB transcriptional activity in activated T cells. J Immunol. 2003;171:3636–44.

53. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008;8:967–75.

54. Semenza GL. Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. EMBO J. 2008;36:252–9.

55. Carlucci A, Adornetto A, Scorziello A, Viggiano D, Cuomo M, et al. Proteolysis of AKAP121 regulates mitochondrial activity during cellular hypoxia and brain ischaemia. EMBO J. 2008;27:1073–84.

56. Shaikh D, Zhou Q, Chen T, Ibe JC, Raj G, et al. cAMP-dependent protein kinase is essential for hypoxia-mediated epithelial-mesenchymal transition, migration, and invasion in lung cancer cells. Cell Signal. 2012;24:2396–406.

57. Taylor SS, Ilouz R, Zhang P, Kornev AP. Assembly of allosteric macromolecular switches: lessons from PKA. Nat Rev Mol Cell Biol. 2012;13:646–58.

58. Tortora G, Pepe S, Bianco C, Baldassarre G, Budillon A, Clair T, et al. The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene. 1994;9:3233–40.

59. Tsigginou A, Bimpaki E, Nesterova M, Horvath A, Boikos S, Lyssikatos C, et al. PRKAR1A gene analysis and protein kinase A activity in endometrial tumors. Endocr Relat Cancer. 2012;19:457–62.

60. Nesterova M, Yokozaki H, McDuffie E, Cho-Chung YS. Over-expression of RII beta regulatory subunit of protein kinase A in human colon carcinoma cell induces growth arrest and phenotypic changes that are abolished by site-directed mutation of RII beta. Eur J Biochem. 1996;235:486–94.

61. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH, et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 2006;66:2725–31.

62. Koshiji M, To KK, Hammer S, Kumamoto K, Harris AL, Modrich P, et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell. 2005;17:793–803.

63. Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 1987;51:1079–90.

64. Kurten RC, Levy LO, Shey J, Durica JM, Richards JS. Identification and characterization of the GC-rich and cyclic adenosine 3’,5’-monophosphate (cAMP)-inducible promoter of the type II beta cAMP-dependent protein kinase regulatory subunit gene. Mol Endocrinol. 1992;6:536–50.

65. Kietzmann T, Mennerich D, Dimova EY. Hypoxia-inducible factors (HIFs) and phosphorylation: impact on stability, localization, and transactivity. Front Cell Dev Biol. 2016;4:11.

66. Pullamsetti SS, Banat GA, Schmall A, Szibor M, Pomagruk D, Hänze J, et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene. 2013;32:1121–34.

67. Toffoli S, Feron O, Raes M, Michiels C, Michiels, Intermittent hypoxia changes HIF-1 alpha phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1 alpha. Biochim Biophys Acta. 2007;1773:1558–71.

68. Bullen JW, Tchernyshyov I, Holewinski RJ, DeVine L, Wu F, Venkataraman V, et al. Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1. Sci Signal. 2016;9:ra56.

69. Cheong HL, Asosingh K, Stephens OR, Queisser KA, Xu W, Willard B, et al. Hypoxia sensing through beta-adrenergic receptors. JCI Insight. 2016;1:e90240.

70. Taylor SS, Yang J, Haste NM, Radzio-Andzelm E, Anand G. PKA: a portrait of protein kinase dynamics. Biochim Biophys Acta. 2004;1697:259–69.

71. Skalhegg BS, Tasken K. Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci. 2000;5:D678–93.